Medicortex is introducing in Finland a new diagnostic method for huge need of brain injury and concussion detection.

- Large customer potential and variable clients.

- Current company valuation ca. 6.3 M€.

- Exit planned as listing* on First North at Nasdaq Helsinki as soon as the valuation is above 10 M€.

- Four people team keeping the costs low, slim and lean organization.

* Pending BOD approval.

Investments will be used for the clinical trial and product development.

- Basic development done including preclinical and proof-of-concept human testing.

- Patent applications and PCT filed.

- Exciting Company, won twice an innovation prize.

Go back to Investors page